A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging
Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in
Adult Subjects with Classic Congenital Adrenal Hyperplasia
Please contact us for more information or to learn if you are eligible to participate.
